Numinus Wellness (TSE:NUMI) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Numinus Wellness Inc. has been greenlit by Health Canada to conduct a groundbreaking study on MDMA-assisted psychotherapy within a group setting, focusing on the therapy’s delivery and the optimal number of therapists required. The clinical trial also offers a unique training opportunity for practitioners to gain firsthand experience and insights into the therapeutic use of MDMA. This research contributes to the evolving understanding and potential integration of psychedelic-assisted treatments in mainstream mental health care.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.